Skip to main content

Ali Ataya, MD

Critical Care Medicine Specialist, Pulmonologist (Lung Specialist)

Rated 4.9 out of 5 stars
Photo of Ali Ataya

About me

My name is Dr. Ataya, and I am an associate professor of medicine in the University of Florida Division of Pulmonary, Critical Care & Sleep Medicine, director of the Pulmonary Hypertension Program and the HHT and Rare Lung Disease Program. I specialize in pulmonary disease, critical care medicine and internal medicine with clinical interest in pulmonary arterial hypertension (PAH), chronic thromboembolic pulmonary hypertension (CTEPH), hereditary hemorrhagic telangiectasia (HHT), lymphangioleiomyomatosis (LAM), pulmonary alveolar proteinosis (PAP) and other rare lung disorders.

My training started at the Royal College of Surgeons in Ireland (RCSI), where I earned my medical degree. I completed my internal medicine residency at the Cleveland Clinic in Ohio. Eventually, I completed my specialty training in pulmonary & critical care medicine here at UF in 2016. I am board certified by the American Board of Critical Care Medicine, American Board of Pulmonary Medicine and the American Board of Internal Medicine.

I maintain a membership of various medical professional societies, including the American Thoracic Society (ATS), America College of Chest Physicians (ACCP) and Pulmonary Hypertension Association (PHA). In addition, I am a strong patient advocate and am actively involved in various patient foundations.

I am involved in various clinical trials in the fields of pulmonary hypertension, intensive care medicine and rare pulmonary diseases.

Accepted insurances

Please note: Some physicians and practices might not accept a specific insurance plan. Our list is also subject to change, and sometimes that change is not yet reflected in this list. Please contact the practice to confirm that your insurance is accepted. A representative will be happy to assist you.

See all insurances

My locations

Active clinical trials

ALN-6400

The purpose of this study is to: evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of ALN-6400 in healthy volunteers evaluate the efficacy, safety, tolerability and PD of multiple doses of…

Investigator
Ali Ataya
Status
Accepting Candidates
Ages
18 Years - N/A
Sexes
All
Decipher
Investigator
Ali Ataya
Status
Accepting Candidates
GB002-3102

This open-label extension study will evaluate the long-term safety, tolerability and efficacy of orally inhaled seralutinib in subjects who have completed a previous seralutinib study

Investigator
Ali Ataya
Status
Accepting Candidates
Ages
18 Years - 75 Years
Sexes
All
View all of Dr. Ataya's active clinical trials

My research

Top areas of exploration

  • Dyspnea , 10 publications
  • Alcohol Drinking , 6 publications
  • Lung Diseases , 5 publications
  • Hypertension, Pulmonary , 5 publications

Research activity

148 publications

733 citations

Why is this important?
View more of Ali Ataya's research activity

My areas of focus

Stories and news

View more stories related to Ali Ataya